Clinical Trials Directory

Trials / Completed

CompletedNCT00091806

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

An Open-Label, Clinical Trial Evaluating the Safety and Pharmacokinetics of Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
86 (actual)
Sponsor
Amgen · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics of two dose schedules of panitumumab in subjects with advanced solid tumors.

Conditions

Interventions

TypeNameDescription
DRUGpanitumumab (ABX-EGF)6 mg/kg once every 2 weeks
DRUGPanitumumab9 mg/kg once every 3 weeks

Timeline

Start date
2004-08-01
Primary completion
2006-04-01
Completion
2006-10-01
First posted
2004-09-21
Last updated
2009-07-10

Source: ClinicalTrials.gov record NCT00091806. Inclusion in this directory is not an endorsement.